Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 4, Pages 531-539
Publisher
Informa Healthcare
Online
2012-03-07
DOI
10.1517/13543784.2012.665871
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.
- (2017) K. T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).
- (2017) G. A. McArthur et al. JOURNAL OF CLINICAL ONCOLOGY
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
- (2017) A. Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
- (2011) Suzanne Leijen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
- (2011) B. Dai et al. CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma
- (2011) Todd D Prickett et al. NATURE GENETICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
- (2010) Jieru Meng et al. CANCER BIOLOGY & THERAPY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
- (2010) S. A. Aziz et al. CLINICAL CANCER RESEARCH
- Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
- (2010) K. Schad et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- Unusual Presentation of Large-Cell Poorly Differentiated Neuroendocrine Carcinoma of the Epiglottis
- (2010) Kevin J. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
- (2010) Marie C. Zipser et al. Pigment Cell & Melanoma Research
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
- (2008) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started